C.A.RE. – MICRODIAGNOSTICS’s Proposal for Tumor-Agnostic and Clinically Actionable Rearrangements

Dr. Garyfalia Karponi

Clinically Actionable REarrangements

Background
Rearrangements (fusions) represent a category of genomic alterations that are attractive both as therapeutic targets and as diagnostic tools, due to their inherent expression exclusively in cancer tissues. In several cancers, rearrangements of specific genes are already pharmacologically targetable, while many of them are found in more than one type of cancer and are therefore characterized as tumor-agnostic.

What we offer

Testing for rearrangements (fusions) in 49 driver genes by NGS — see table below
In selected genes — ALK, FGFR2, NTRK1, NTRK2, NTRK3 and RET — the panel can also detect novel rearrangements, beyond the known literature-defined rearrangements, through Exon Tile Imbalance technology
In selected genes — AR, BRAF, BRCA1, EGFR, MET, NTRK1 and RELA — the panel can detect intragenic exon rearrangements and accurately predict exon skipping through RNA Exon Variant technology

AKT1 ERBB4 (HER4) MET NTRK3 RET
AKT2 ERG MTAP NUTM1 ROS1
AKT3 ESR1 MYB PIK3CA RSPO2
ALK ETV1 MYBL1 PIK3CB RSPO3
AR ETV4 NOTCH1 PPARG STAT6
BRAF ETV5 NOTCH2 PRKACA TERT
BRCA1 FGFR1 NOTCH3 PRKACB TFE3
CDKN2A FGFR2 NRG1 RAF1 TFEB
EGFR FGFR3 NTRK1 RARA YAP1
ERBB2 (HER2) MAP3K8 NTRK2 RELA

 

Required sample: Formalin-fixed paraffin-embedded tissue (FFPE)

Turnaround time: 2 weeks

Please contact us for more information.

Garyfalia Karponi, MSc, PhD

Molecular Biologist-Geneticist

Chief Scientific Officer, Department of Molecular Diagnostics